Asian Market: 3 Stocks That May Be Trading Below Estimated Value

Dec 18, 2025
asian-market:-3-stocks-that-may-be-trading-below-estimated-value

Simply Wall St

4 min read

As global markets experience fluctuations with interest rate adjustments and economic uncertainties, Asian stocks present unique opportunities for investors seeking value. In this context, identifying undervalued stocks involves assessing factors such as company fundamentals, market position, and the broader economic environment to uncover potential investments that may be trading below their estimated value.

Name

Current Price

Fair Value (Est)

Discount (Est)

Xi’an NovaStar Tech (SZSE:301589)

CN¥153.67

CN¥303.69

49.4%

Wuhan Guide Infrared (SZSE:002414)

CN¥12.86

CN¥25.28

49.1%

Sany Heavy Equipment International Holdings (SEHK:631)

HK$8.24

HK$16.21

49.2%

Mobvista (SEHK:1860)

HK$15.47

HK$30.70

49.6%

KoMiCo (KOSDAQ:A183300)

₩84300.00

₩166235.75

49.3%

JINS HOLDINGS (TSE:3046)

¥5480.00

¥10936.95

49.9%

Global Security Experts (TSE:4417)

¥2896.00

¥5752.68

49.7%

FIT Hon Teng (SEHK:6088)

HK$5.65

HK$11.25

49.8%

Beijing HyperStrong Technology (SHSE:688411)

CN¥259.34

CN¥517.30

49.9%

ActRO (KOSDAQ:A290740)

₩12750.00

₩25049.37

49.1%

Click here to see the full list of 282 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Let’s take a closer look at a couple of our picks from the screened companies.

Overview: AprilBio Co., Ltd. develops long-acting biobetter and antibody biologics, with a market cap of ₩1.03 trillion.

Operations: AprilBio Co., Ltd. does not have specified revenue segments available in the provided text.

Estimated Discount To Fair Value: 26.4%

AprilBio Ltd. is trading at ₩44,300, which is 26.4% below its estimated fair value of ₩60,203.7, indicating it may be undervalued based on cash flows. Despite recent share price volatility, the company is expected to achieve profitability within three years with earnings projected to grow by a very large margin annually and revenue growth forecasted at 79.2% per year—significantly outpacing the Korean market’s average growth rate of 10.6%.

KOSDAQ:A397030 Discounted Cash Flow as at Dec 2025

KOSDAQ:A397030 Discounted Cash Flow as at Dec 2025

Overview: Angelalign Technology Inc. is an investment holding company that specializes in the research, design, manufacture, sale, and marketing of clear aligner treatment solutions both in the People’s Republic of China and internationally, with a market cap of approximately HK$10.44 billion.

Operations: The company’s revenue is primarily derived from its Dental Equipment & Supplies segment, which generated $308.87 million.


Leave a comment